Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. Xiong W, et al. Among authors: papasouliotis o. Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30. Cancer Chemother Pharmacol. 2022. PMID: 35771259 Free PMC article. Clinical Trial.
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.
Kareva I, Zutshi A, Mateo CV, Papasouliotis O. Kareva I, et al. Among authors: papasouliotis o. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34328632 Free PMC article. Review.
Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.
Kareva I, Zutshi A, Mateo CV, Papasouliotis O. Kareva I, et al. Among authors: papasouliotis o. Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):827. doi: 10.1007/s13318-021-00719-8. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34581976 Free PMC article. No abstract available.
Kinetics of free and ligand-bound atacicept in human serum.
Eslami M, Willen D, Papasouliotis O, Schuepbach-Mallpell S, Willen L, Donzé O, Yalkinoglu Ö, Schneider P. Eslami M, et al. Among authors: papasouliotis o. Front Immunol. 2022 Dec 2;13:1035556. doi: 10.3389/fimmu.2022.1035556. eCollection 2022. Front Immunol. 2022. PMID: 36532058 Free PMC article.
23 results